Table of Contents Author Guidelines Submit a Manuscript
International Journal of Alzheimer’s Disease
Volume 2010, Article ID 610613, 5 pages
http://dx.doi.org/10.4061/2010/610613
Review Article

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease

The Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska University Hospital, The Sahlgrenska Academy at University of Gothenburg, 43180 Mölndal, Sweden

Received 19 April 2010; Accepted 10 May 2010

Academic Editor: Lucilla Parnetti

Copyright © 2010 Niklas Mattsson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Blennow, H. Hampel, M. Weiner, and H. Zetterberg, “Cerebrospinal fluid and plasma biomarkers in Alzheimer disease,” Nature Reviews Neurology, vol. 6, no. 3, pp. 131–144, 2010. View at Publisher · View at Google Scholar · View at PubMed
  2. G. B. Frisoni et al., “The clinical use of structural MRI in Alzheimer disease,” Nature Reviews Neurology, vol. 6, no. 2, pp. 67–77, 2010. View at Google Scholar
  3. A. Nordberg, J. O. Rinne, A. Kadir, and B. Lngström, “The use of PET in Alzheimer disease,” Nature Reviews Neurology, vol. 6, no. 2, pp. 78–87, 2010. View at Publisher · View at Google Scholar · View at PubMed
  4. D. Strozyk, K. Blennow, L. R. White, and L. J. Launer, “CSF Aß 42 levels correlate with amyloid-neuropathology in a population-based autopsy study,” Neurology, vol. 60, no. 4, pp. 652–656, 2003. View at Google Scholar
  5. T. Tapiola, I. Alafuzoff, S.-K. Herukka, L. Parkkinen, P. Hartikainen, H. Soininen, and T. Pirttilä, “Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain,” Archives of Neurology, vol. 66, no. 3, pp. 382–389, 2009. View at Publisher · View at Google Scholar · View at PubMed
  6. A. M. Fagan, M. A. Mintun, and M. A. Mintun, “Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans,” Annals of Neurology, vol. 59, no. 3, pp. 512–519, 2006. View at Publisher · View at Google Scholar · View at PubMed
  7. A. Forsberg, H. Engler, and H. Engler, “PET imaging of amyloid deposition in patients with mild cognitive impairment,” Neurobiology of Aging, vol. 29, no. 10, pp. 1456–1465, 2008. View at Publisher · View at Google Scholar · View at PubMed
  8. K. Blennow and H. Hampel, “CSF markers for incipient Alzheimer's disease,” Lancet Neurology, vol. 2, no. 10, pp. 605–613, 2003. View at Publisher · View at Google Scholar
  9. N. Mattsson, K. Blennow, and H. Zetterberg, “CSF biomarkers: pinpointing alzheimer pathogenesis,” Annals of the New York Academy of Sciences, vol. 1180, pp. 28–35, 2009. View at Publisher · View at Google Scholar · View at PubMed
  10. H. Hampel, K. Blennow, L. M. Shaw, Y. C. Hoessler, H. Zetterberg, and J. Q. Trojanowski, “Total and phosphorylated tau protein as biological markers of Alzheimer's disease,” Experimental Gerontology, vol. 45, no. 1, pp. 30–40, 2010. View at Publisher · View at Google Scholar · View at PubMed
  11. C. R. Jack Jr., D. S. Knopman, and D. S. Knopman, “Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade,” The Lancet Neurology, vol. 9, no. 1, pp. 119–128, 2010. View at Publisher · View at Google Scholar
  12. O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow, and L. Minthon, “Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study,” Lancet Neurology, vol. 5, no. 3, pp. 228–234, 2006. View at Publisher · View at Google Scholar · View at PubMed
  13. “Consensus report of the Working Group on: “molecular and biochemical markers of Alzheimer's disease”. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group,” Neurobiology of Aging, vol. 19, no. 2, pp. 109–116, 1998. View at Publisher · View at Google Scholar
  14. M. Riemenschneider, N. Lautenschlager, S. Wagenpfeil, J. Diehl, A. Drzezga, and A. Kurz, “Cerebrospinal fluid tau and β-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment,” Archives of Neurology, vol. 59, no. 11, pp. 1729–1734, 2002. View at Publisher · View at Google Scholar
  15. H. Zetterberg, L.-O. Wahlund, and K. Blennow, “Cerebrospinal fluid markers for prediction of Alzheimer's disease,” Neuroscience Letters, vol. 352, no. 1, pp. 67–69, 2003. View at Publisher · View at Google Scholar
  16. N. Andreasen, E. Vanmechelen, H. Vanderstichele, P. Davidsson, and K. Blennow, “Cerebrospinal fluid levels of total-tau, phospho-tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment,” Acta Neurologica Scandinavica, Supplement, vol. 179, pp. 47–51, 2003. View at Google Scholar
  17. H. Hampel, S. J. Teipel, and S. J. Teipel, “Value of CSF β-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment,” Molecular Psychiatry, vol. 9, no. 7, pp. 705–710, 2004. View at Google Scholar
  18. S.-K. Herukka, M. Hallikainen, H. Soininen, and T. Pirttilä, “CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment,” Neurology, vol. 64, no. 7, pp. 1294–1297, 2005. View at Google Scholar
  19. S.-K. Herukka, S. Helisalmi, M. Hallikainen, S. Tervo, H. Soininen, and T. Pirttilä, “CSF Aβ42, Tau and phosphorylated Tau, APOE ε4 allele and MCI type in progressive MCI,” Neurobiology of Aging, vol. 28, no. 4, pp. 507–514, 2007. View at Publisher · View at Google Scholar · View at PubMed
  20. N. Andreasen, L. Minthon, E. Vanmechelen, H. Vanderstichele, P. Davidsson, B. Winblad, and K. Blennow, “Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment,” Neuroscience Letters, vol. 273, no. 1, pp. 5–8, 1999. View at Publisher · View at Google Scholar
  21. P. J. Visser, F. Verhey, and F. Verhey, “Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study,” The Lancet Neurology, vol. 8, no. 7, pp. 619–627, 2009. View at Publisher · View at Google Scholar
  22. F. Hulstaert, K. Blennow, and K. Blennow, “Improved discrimination of AD patients using β-amyloid((1-42)) and tau levels in CSF,” Neurology, vol. 52, no. 8, pp. 1555–1562, 1999. View at Google Scholar
  23. G. M. Savva, S. B. Wharton, P. G. Ince, G. Forster, F. E. Matthews, and C. Brayne, “Age, neuropathology, and dementia,” New England Journal of Medicine, vol. 360, no. 22, pp. 2302–2309, 2009. View at Publisher · View at Google Scholar · View at PubMed
  24. G. Li, I. Sokal, and I. Sokal, “CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment: a follow-up study,” Neurology, vol. 69, no. 7, pp. 631–639, 2007. View at Publisher · View at Google Scholar · View at PubMed
  25. E. Stomrud, O. Hansson, K. Blennow, L. Minthon, and E. Londos, “Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly,” Dementia and Geriatric Cognitive Disorders, vol. 24, no. 2, pp. 118–124, 2007. View at Publisher · View at Google Scholar · View at PubMed
  26. K. E. Pike, G. Savage, and G. Savage, “β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease,” Brain, vol. 130, no. 11, pp. 2837–2844, 2007. View at Publisher · View at Google Scholar · View at PubMed
  27. M. A. Mintun, G. N. Larossa, and G. N. Larossa, “[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease,” Neurology, vol. 67, no. 3, pp. 446–452, 2006. View at Publisher · View at Google Scholar · View at PubMed
  28. C. A. Wiley, B. J. Lopresti, S. Venneti, J. Price, W. E. Klunk, S. T. DeKosky, and C. A. Mathis, “Carbon 11-labeled Pittsburgh compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease,” Archives of Neurology, vol. 66, no. 1, pp. 60–67, 2009. View at Publisher · View at Google Scholar · View at PubMed
  29. E. Stomrud, O. Hansson, H. Zetterberg, K. Blennow, L. Minthon, and E. Londos, “Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults,” Archives of Neurology, vol. 67, no. 2, pp. 217–223, 2010. View at Publisher · View at Google Scholar · View at PubMed
  30. T. Hedden, K. R. A. Van Dijk, J. A. Becker, A. Mehta, R. A. Sperling, K. A. Johnson, and R. L. Buckner, “Disruption of functional connectivity in clinically normal older adults harboring amyloid burden,” Journal of Neuroscience, vol. 29, no. 40, pp. 12686–12694, 2009. View at Publisher · View at Google Scholar · View at PubMed
  31. L. M. Shaw, H. Vanderstichele, and H. Vanderstichele, “Cerebrospinal fluid biomarker signature in alzheimer's disease neuroimaging initiative subjects,” Annals of Neurology, vol. 65, no. 4, pp. 403–413, 2009. View at Publisher · View at Google Scholar · View at PubMed
  32. N. Mattsson, H. Zetterberg, and H. Zetterberg, “CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment,” Journal of the American Medical Association, vol. 302, no. 4, pp. 385–393, 2009. View at Publisher · View at Google Scholar · View at PubMed
  33. N. Mattsson, K. Blennow, and H. Zetterberg, “Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall,” Clinical Chemistry and Laboratory Medicine, vol. 48, no. 5, pp. 603–607, 2010. View at Publisher · View at Google Scholar · View at PubMed
  34. P. Lewczuk, G. Beck, and G. Beck, “Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid β peptides,” Clinical Chemistry, vol. 52, no. 2, pp. 332–334, 2006. View at Publisher · View at Google Scholar · View at PubMed
  35. N. S. M. Schoonenboom, C. Mulder, and C. Mulder, “Effects of processing and storage conditions on amyloid β (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice,” Clinical Chemistry, vol. 51, no. 1, pp. 189–195, 2005. View at Publisher · View at Google Scholar · View at PubMed
  36. P. Lewczuk, G. Beck, and G. Beck, “International quality control survey of neurochemical dementia diagnostics,” Neuroscience Letters, vol. 409, no. 1, pp. 1–4, 2006. View at Publisher · View at Google Scholar · View at PubMed
  37. N. A. Verwey, W. M. Van Der Flier, and W. M. Van Der Flier, “A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease,” Annals of Clinical Biochemistry, vol. 46, no. 3, pp. 235–240, 2009. View at Publisher · View at Google Scholar · View at PubMed
  38. A. Olsson, H. Vanderstichele, and H. Vanderstichele, “Simultaneous measurement of β-amyloid(1-42), total Tau, and phosphorylated Tau (Thr181) in cerebrospinal fluid by the xMAP technology,” Clinical Chemistry, vol. 51, no. 2, pp. 336–345, 2005. View at Publisher · View at Google Scholar · View at PubMed
  39. T. S. M. Reijn, M. O. Rikkert, W. J. A. Van Geel, D. De Jong, and M. M. Verbeek, “Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid β42 and tau proteins,” Clinical Chemistry, vol. 53, no. 5, pp. 859–865, 2007. View at Publisher · View at Google Scholar · View at PubMed
  40. P. Lewczuk, J. Kornhuber, and J. Wiltfang, “The German Competence Net Dementias: standard operating procedures for the neurochemical dementia diagnostics,” Journal of Neural Transmission, vol. 113, no. 8, pp. 1075–1080, 2006. View at Publisher · View at Google Scholar · View at PubMed